이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immunovia 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Philipp Mathieu

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.009%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	5.5yrs

최근 관리 업데이트

Recent updates

CEO

Philipp Mathieu

less than a year

테뉴어

Mr. Philipp Mathieu serves as Chief Executive Officer and President at Immunovia AB (publ) since June 02, 2022. Mr. Mathieu served as an Acting CEO & President of Immunovia AB (publ) since January 20, 2022...

리더십 팀

이름	위치	테뉴어	보상	소유권
Philipp Mathieu	CEO & President	less than a year	데이터 없음	0.0093% SEK 51.4k
Karin Liwendahl	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Jeff Borcherding	Chief Executive Officer of US	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

경험이 풍부한 관리: IMMNOS 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Carl Arne Borrebaeck	Independent Chairman of the Board	16yrs	SEK 580.00k	7.56% SEK 41.7m
Hans Johansson	Independent Director	6yrs	SEK 288.00k	0.14% SEK 761.7k
Margaret Tempero	Member of Scientific Advisory Board	6.6yrs	데이터 없음	데이터 없음
Philipp Sixt Von Hugo	Independent Director	less than a year	데이터 없음	데이터 없음
Diane Simeone	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음
Stephen Pereira	Member of Scientific Advisory Board	5.5yrs	데이터 없음	데이터 없음
Eric Krafft	Independent Director	less than a year	데이터 없음	데이터 없음
Peter Andersen	Independent Director	2.7yrs	SEK 268.00k	0.052% SEK 286.0k
Martin Moller	Director	1.7yrs	SEK 160.00k	0.0047% SEK 25.8k

5.5yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: IMMNOS 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.

Immunovia 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Immunovia AB (Publ) Announces Board Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently bought kr186k worth of stock

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Iimmunovia AB (Publ) Publishes Data Sets on the Optimization Study and Commercial Test Model Study

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

Revenue in line with expectations

Immunovia AB (publ) to Report Q1, 2021 Results on Apr 28, 2021

Immunovia's PanFAM Prospective Study Gathers over 3000 Familial Hereditary Pancreatic Cancer Risk Samples and Will Be Analysed in the Second Half of 2021

Immunovia AB Announces Results from Study in Their Development Pipeline

New 90-day low: kr111

Director recently bought kr144k worth of stock

New 90-day low: kr122

Immunovia AB (Publ) Announces Appointment of Members of Nomination Committee

Immunovia AB (publ) Announces Management Changes

Immunovia AB (Publ) Announces Completion of Analysis from the Immray Pancan-D Verification Study

Immunovia Announces Positive Results from the Immray Pancan-D Verification Study

Immunovia AB (Publ) Appoints Mats Grahn as New Member of the Board of Directors

Immunovia Announces CEO Transition, Effective November 1, 2020

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령